BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 29571585)

  • 1. Molecular Progression Risk Score for Prediction of Muscle Invasion in Primary T1 High-Grade Bladder Cancer.
    Kang HW; Seo SP; Byun YJ; Piao XM; Kim YH; Jeong P; Ha YS; Kim WT; Kim YJ; Lee SC; Moon SK; Choi YH; Yun SJ; Kim WJ
    Clin Genitourin Cancer; 2018 Aug; 16(4):274-280. PubMed ID: 29571585
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Impact of a 12-gene Progression Score in Non-muscle-invasive Bladder Cancer: A Prospective Multicentre Validation Study.
    Dyrskjøt L; Reinert T; Algaba F; Christensen E; Nieboer D; Hermann GG; Mogensen K; Beukers W; Marquez M; Segersten U; Høyer S; Ulhøi BP; Hartmann A; Stöhr R; Wach S; Nawroth R; Schwamborn K; Tulic C; Simic T; Junker K; Harving N; Petersen AC; Jensen JB; Keck B; Grimm MO; Horstmann M; Maurer T; Steyerberg EW; Zwarthoff EC; Real FX; Malats N; Malmström PU; Ørntoft TF
    Eur Urol; 2017 Sep; 72(3):461-469. PubMed ID: 28583312
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High expression of long noncoding RNA NORAD indicates a poor prognosis and promotes clinical progression and metastasis in bladder cancer.
    Li Q; Li C; Chen J; Liu P; Cui Y; Zhou X; Li H; Zu X
    Urol Oncol; 2018 Jun; 36(6):310.e15-310.e22. PubMed ID: 29605462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histological and immunohistochemical markers for progression prediction in transurethrally resected high-grade non-muscle invasive bladder cancer.
    Kim K; Cho YM; Park BH; Lee JL; Ro JY; Go H; Shim JW
    Int J Clin Exp Pathol; 2015; 8(1):743-50. PubMed ID: 25755769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictive value of progression-related gene classifier in primary non-muscle invasive bladder cancer.
    Kim WJ; Kim EJ; Kim SK; Kim YJ; Ha YS; Jeong P; Kim MJ; Yun SJ; Lee KM; Moon SK; Lee SC; Cha EJ; Bae SC
    Mol Cancer; 2010 Jan; 9():3. PubMed ID: 20059769
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary expression of let-7c cluster as non-invasive tool to assess the risk of disease progression in patients with high grade non-muscle invasive bladder Cancer: a pilot study.
    Spagnuolo M; Costantini M; Ferriero M; Varmi M; Sperduti I; Regazzo G; Cicchillitti L; Díaz Méndez AB; Cigliana G; Pompeo V; Russo A; Laquintana V; Mastroianni R; Piaggio G; Anceschi U; Brassetti A; Bove A; Tuderti G; Flammia RS; Gallucci M; Simone G; Rizzo MG
    J Exp Clin Cancer Res; 2020 Apr; 39(1):68. PubMed ID: 32303246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of caldesmon is associated with tumor progression in patients with primary non-muscle-invasive bladder cancer.
    Lee MS; Lee J; Kim JH; Kim WT; Kim WJ; Ahn H; Park J
    Oncotarget; 2015 Nov; 6(37):40370-84. PubMed ID: 26430961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression signature defined by FOXM1-CCNB1 activation predicts disease recurrence in non-muscle-invasive bladder cancer.
    Kim SK; Roh YG; Park K; Kang TH; Kim WJ; Lee JS; Leem SH; Chu IS
    Clin Cancer Res; 2014 Jun; 20(12):3233-43. PubMed ID: 24714775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
    Kawakami K; Enokida H; Tachiwada T; Gotanda T; Tsuneyoshi K; Kubo H; Nishiyama K; Takiguchi M; Nakagawa M; Seki N
    Oncol Rep; 2006 Sep; 16(3):521-31. PubMed ID: 16865252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phospho-Akt pathway activation and inhibition depends on N-cadherin or phospho-EGFR expression in invasive human bladder cancer cell lines.
    Wallerand H; Cai Y; Wainberg ZA; Garraway I; Lascombe I; Nicolle G; Thiery JP; Bittard H; Radvanyi F; Reiter RR
    Urol Oncol; 2010; 28(2):180-8. PubMed ID: 19070520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High expression of spindle and kinetochore- associated protein 1 predicts early recurrence and progression of non-muscle invasive bladder cancer.
    Jiang S; Tian F; Wang Q; Cheng W; Wang L; Wang Y; Sun W
    Cancer Biomark; 2018; 22(3):543-549. PubMed ID: 29865039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical implications and prognostic values of topoisomerase-II alpha expression in primary non-muscle-invasive bladder cancer.
    Kim EJ; Lee YS; Kim YJ; Kim MJ; Ha YS; Jeong P; Lee OJ; Kim WJ
    Urology; 2010 Jun; 75(6):1516.e9-13. PubMed ID: 19913893
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of zinc finger E-box binding homeobox 1 and transforming growth factor-beta2 expression in bladder cancer tissue in comparison with healthy adjacent tissue.
    Mahdavinezhad A; Yadegarazari R; Mousavi-Bahar SH; Poorolajal J; Jafari M; Amirzargar MA; Effatpanah H; Saidijam M
    Investig Clin Urol; 2017 Mar; 58(2):140-145. PubMed ID: 28261684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guerin intravesical therapy?
    Park J; Song C; Shin E; Hong JH; Kim CS; Ahn H
    Urol Oncol; 2013 Aug; 31(6):849-56. PubMed ID: 21782482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum microRNA expression signatures as novel noninvasive biomarkers for prediction and prognosis of muscle-invasive bladder cancer.
    Jiang X; Du L; Duan W; Wang R; Yan K; Wang L; Li J; Zheng G; Zhang X; Yang Y; Wang C
    Oncotarget; 2016 Jun; 7(24):36733-36742. PubMed ID: 27167342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinicopathological analysis of patients with non-muscle-invasive bladder cancer: prognostic value and clinical reliability of the 2004 WHO classification system.
    Nishiyama N; Kitamura H; Maeda T; Takahashi S; Masumori N; Hasegawa T; Tsukamoto T
    Jpn J Clin Oncol; 2013 Nov; 43(11):1124-31. PubMed ID: 23980236
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High insulin-like growth factor mRNA-binding protein 3 (IMP3) protein expression is associated with poor survival in muscle-invasive bladder cancer.
    Szarvas T; vom Dorp F; Niedworok C; Melchior-Becker A; Fischer JW; Singer BB; Reis H; Bánkfalvi Á; Schmid KW; Romics I; Ergün S; Rübben H
    BJU Int; 2012 Sep; 110(6 Pt B):E308-17. PubMed ID: 22500655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling Nutritional Status Score Evaluates Prognosis in Patients With Non-Muscle Invasive Bladder Cancer.
    Huang J; Zhao L; Wang K; Sun J; Tai S; Hua R; Yu Y; Fan Y
    Cancer Control; 2021; 28():10732748211021078. PubMed ID: 34060373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.